CEO saved millions by selling vaccine stock before value tanked: report
New security filings show how one CEO saved himself millions by dumping stock in his own company.
“The stock price of government contractor Emergent BioSolutions has fallen sharply since the disclosure at the end of March that production problems at the firm’s plant in Baltimore had ruined 15 million doses of Johnson & Johnson’s coronavirus vaccine. Since then, AstraZeneca moved production of its own vaccine out of the facility, and Emergent temporarily halted work there altogether,” The Washington…
